Abstract
Bivalirudin, a direct thrombin inhibitor, has recently emerged as a promising option for anti-coagulation during cardiopulmonary bypass in patients who cannot receive heparin. There is limited experience with the use of bivalirudin in children. We present the case of a child with heparin-induced thrombocytopenia with thrombosis (HIT Type II) who underwent successful orthotopic cardiac transplantation using bivalirudin as the primary anti-coagulant for cardiopulmonary bypass.
MeSH terms
-
Anticoagulants / adverse effects
-
Anticoagulants / therapeutic use*
-
Cardiopulmonary Bypass / methods
-
Child, Preschool
-
Dose-Response Relationship, Drug
-
Female
-
Heart Transplantation*
-
Heparin / adverse effects*
-
Hirudins / adverse effects
-
Humans
-
Peptide Fragments / adverse effects
-
Peptide Fragments / therapeutic use*
-
Postoperative Complications / drug therapy
-
Postoperative Complications / prevention & control
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / therapeutic use
-
Thrombin / antagonists & inhibitors
-
Thrombocytopenia / chemically induced*
-
Thrombosis / drug therapy
-
Thrombosis / prevention & control
Substances
-
Anticoagulants
-
Hirudins
-
Peptide Fragments
-
Recombinant Proteins
-
Heparin
-
Thrombin
-
bivalirudin